Association of changes in norepinephrine and serotonin transporter expression with the long-term behavioral effects of antidepressant drugs.
D000818:Animals; D018687:Antidepressive Agents, Second-Generation / Q000494:pharmacology*; D000929:Antidepressive Agents, Tricyclic / Q000494:pharmacology*; D001921:Brain / Q000187:drug effects* / Q000378:metabolism; D003511:Cyclohexanols / Q000494:pharmacology; D003863:Depression / Q000188:drug therapy / Q000503:physiopathology; D015536:Down-Regulation / Q000187:drug effects; D010134:Fenclonine / Q000494:pharmacology; D008297:Male; D008996:Monoamine Oxidase Inhibitors / Q000494:pharmacology; D009025:Morpholines / Q000494:pharmacology; D050484:Norepinephrine Plasma Membrane Transport Proteins / Q000235:genetics / Q000378:metabolism*; D010624:Phenelzine / Q000494:pharmacology; D011500:Protein Synthesis Inhibitors / Q000494:pharmacology; D011530:Protriptyline / Q000494:pharmacology; D012333:RNA, Messenger / Q000378:metabolism; D051381:Rats; D017207:Rats, Sprague-Dawley; D000077593:Reboxetine; D012702:Serotonin Antagonists / Q000494:pharmacology; D050486:Serotonin Plasma Membrane Transport Proteins / Q000235:genetics / Q000378:metabolism*; D017367:Selective Serotonin Reuptake Inhibitors / Q000494:pharmacology; D020280:Sertraline / Q000494:pharmacology; D000069470:Venlafaxine Hydrochloride
D018687:Antidepressive Agents, Second-Generation; D000929:Antidepressive Agents, Tricyclic; D003511:Cyclohexanols; D010134:Fenclonine; D008996:Monoamine Oxidase Inhibitors; D009025:Morpholines; D050484:Norepinephrine Plasma Membrane Transport Proteins; D010624:Phenelzine; D011500:Protein Synthesis Inhibitors; D011530:Protriptyline; D012333:RNA, Messenger; D000077593:Reboxetine; D012702:Serotonin Antagonists; D050486:Serotonin Plasma Membrane Transport Proteins; D017367:Selective Serotonin Reuptake Inhibitors; D020280:Sertraline; D000069470:Venlafaxine Hydrochloride; C493226:Slc6a2 protein, rat; C493232:Slc6a4 protein, rat